A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 197 participants.

Also called NCT01691989

  • Study
  • In this atlas

Overview

Design
Interventional study; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 197 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01691989
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Colombia, Guatemala, Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01691989. Double masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2013-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy
Condition
Diabetes Mellitus Type 2
Intervention (Drug)
aleglitazar
Intervention (Drug)
placebo
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct01691989
Content hash
84d9d5dc58ccd6a700e438aa87af4c6cd28eb7c39afff7fd2ad63ab5dc94cd46